Search research articles
Contact Us
Filters
Showing results (191-200 of 228) with videos related to
Page
of 23
Sort By:
Targeted Oncology
|
December 11, 2025
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study
Alba Rubio-San-Simón, Lynley V Marshall, Francois Doz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART
Birgit Geoerger, Francisco Bautista, Nicolas André, et al.
Pediatric Blood & Cancer
|
March 17, 2026
The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience
Thomas J Jackson, Menna Shamma, Upeka Senanayake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study
Lucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
ESMO Open
|
February 5, 2025
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma
M Casanova, C M Albert, F Bautista, et al.
Biomedical Optics Express
|
May 11, 2012
Seeing it through: translational validation of new medical imaging modalities
Melissa B Aldrich, Milton V Marshall, Eva M Sevick-Muraca, et al.
The Lancet. Oncology
|
July 6, 2017
From class waivers to precision medicine in paediatric oncology
Andrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Nature Medicine
|
October 19, 2023
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
Birgit Geoerger, Xavier Paoletti, Francisco Bautista, et al.
The Lancet. Oncology
|
December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Neuro-Oncology Advances
|
June 25, 2021
Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
Elisa Izquierdo, Paula Proszek, Giulia Pericoli, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 228) with videos related to
Sort By:
Page
of 23
Targeted Oncology
|
December 11, 2025
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study
Alba Rubio-San-Simón, Lynley V Marshall, Francois Doz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART
Birgit Geoerger, Francisco Bautista, Nicolas André, et al.
Pediatric Blood & Cancer
|
March 17, 2026
The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience
Thomas J Jackson, Menna Shamma, Upeka Senanayake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study
Lucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
ESMO Open
|
February 5, 2025
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma
M Casanova, C M Albert, F Bautista, et al.
Biomedical Optics Express
|
May 11, 2012
Seeing it through: translational validation of new medical imaging modalities
Melissa B Aldrich, Milton V Marshall, Eva M Sevick-Muraca, et al.
The Lancet. Oncology
|
July 6, 2017
From class waivers to precision medicine in paediatric oncology
Andrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Nature Medicine
|
October 19, 2023
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
Birgit Geoerger, Xavier Paoletti, Francisco Bautista, et al.
The Lancet. Oncology
|
December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
Neuro-Oncology Advances
|
June 25, 2021
Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
Elisa Izquierdo, Paula Proszek, Giulia Pericoli, et al.
Page
of 23